- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03325088
Assessing the Expression and the Activity of Rac1 Protein in the Airway Smooth Muscle of Asthmatic Patient (NaRacAS)
Assessing the Expression and the Activity of Rac1 Protein in the Airway Smooth Muscle of
Asthma is a chronic inflammatory respiratory disease affecting 6 to 7% of the French adult population and responsible of 1000 deaths in France every year. Many anti-inflammatory treatments are available but few had been developed to target hyperresponsiveness.Investigators and searchers of the Institut du thorax have recently demonstrated the main involvement of Rac1 monomeric G protein in the contraction of airway smooth muscle cells. They show that Rac1 is expressed in the airway smooth muscle cells in mice and its activity is increased in the bronchi of asthma induced mice sensitized to House-Dust Mite. They further demonstrate that Rac1 inhibition in mice by nebulisation reduces airway hyperresponsiveness and pulmonary inflammation. Investigators and searchers of the Institut du thorax would like to seek whether targeting Rac1 would be interesting in asthmatic patients. Primary objective of this study is to determine if Rac1 expression and activity in airway smooth muscle cells are increased in asthmatic patients compare to controlled samples (deceased donor samples). Secondary objective is to determine whether there is a correlation between Rac1 activity and asthma severity.
If Rac1 activity in airway smooth muscles is indeed increased in asthmatic patients depending on asthma severity, Rac1 could be a potential target to treat airway hyperresponsiveness.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients will be openly labeled in one of the following group
- 15 patients with severe asthma, without oral corticosteroids treatment.,
- 6 patients with mild to moderate asthma without treatment,
- 21 controlled samples from smooth muscle cells of non-asthmatic deceased donor Bronchial endoscopy with bronchial biopsies will be assessed in all asthmatic patients, Control samples will be obtained from tracheobronchial rings of cadaveric donor. Expression and activity of Rac1 in airway smooth muscle will be determined by immuno-staining on paraffinised biopsies.
Patients will undergo two study visits (D0: inclusion visit, D15: exploratory visit) and one phone call at D21.
Inclusion Visit (D0):
- Signature of the Informed consent,
- Medical History,
- Clinical examination,
- Pulmonary Function Test,
- Blood samples for fibroscopy safety,
- ACT (Asthma Control Test), ACQ (Asthma Control Questionnaire), AQLQ (Asthma Quality of Life Questionnaire), Morisky questionnaire
Exploratory visit (D15)
- Clinical examination,
- Bronchial endoscopy with biopsies Adverse event
Phone Call (D21)
- Adverse event
Recruitment will last 4 years.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: François-Xavier BLANC, Pr
- Phone Number: +33(0)240165533
- Email: xavier.blanc@chu-nantes.fr
Study Contact Backup
- Name: François-Xavier BLANC
- Phone Number: +33(0)240165533
- Email: xavier.blanc@chu-nantes.fr
Study Locations
-
-
-
Nantes, France
- University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Asthmatic Patient :
- Male or Female from 18 to 70 years old,
Diagnosis of asthma confirmed by
- Existence of one or more following symptoms over 3 months at least (wheezing dyspnea, wheezing, chronic cough and tightness in the chest…)
- AND past pulmonary function test showing a reversible obstructive ventilatory syndrome after inhaled short-acting bronchodilators (improvement of FEV1 above 12% and at least 200 mL FEV1 gain compare to pre-bronchodilatator FEV1)
- AND a removal of the clinically suspected differential diagnoses of asthma (vocal cord dysfunction, Churg-Strauss syndrome etc…). The comorbidities should have been explored and treated or on treatment at enrollment.
- Subject agreed to participate to the study and the biological samples collection,
- Subject is affiliate to a social security system.
- Inclusion criteria for severe asthmatic patient :
Patient with one of the following criterion will be considered as severe asthmatic patient :
- Patient with a controlled asthma but using high dose of inhaled corticosteroids with another therapeutic classes,
- OR Patient with uncontrolled asthma despite treatment,
OR Patient with worsening asthma despite treatment.
-->Inclusion criteria for non-severe asthmatic patients :
Moderate Asthmatic patient without standard of care treatment since at least one week before the exploratory visit.
-->Controlled sample:
- Non asthmatic cadaveric adults
Exclusion Criteria:
Asthmatic Patient :
- Underage,
- Pregnant or breast-feeding women,
- Adult on guardianship
- Active smoker (smoked or Inhaled),
- former smokers (smoked or Inhaled) with a smoking history of ≥10 pack years since less than 5 years.
- Patient with asthma exacerbation the 4 past weeks before the exploratory visit..
- Patient treated by long term oral corticosteroids or ongoing biological therapy or stopped within the 3 months before exploratory visit.
- Patient with severe acute or chronic organ disorder (cardiovascular, respiratory, hepatic, renal, malabsorption)
- Patient with history of unstable angina,
- Patient with platelet count abnormality, or primary or acquired thrombopathy, or an aPTT (activated Partial Thromboplastin Time) greater than or equal to 1,5 times normal or patient with a Quick Time > 26 seconds
- Patient under a systemic immunomodulatory or immunosuppressive treatment
- Patient with anticoagulants or anti-platelet aggregating drugs other than D-lysin acetylsalicylate and that could not be suspended before the bronchial fibroscopy.
- Patient with hypersensitivity to the treatment used during the bronchial fibroscopy: Hydroxyzine, Midazolam, Xylocaine.
- Patient with AME (Government Medical Assistance),
- Patient having physical and psychological disabilities to follow the protocol,
- Patient included in another interventional research protocol,
- Patient having risk factors of Creutzfeld-Jakob disease
Controlled sample:
- Asthmatic patient
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Severe Asthma
patients affected with severe asthma s defined by ERS-ATS (European Respiratory Society - American Thoracic Society) without long term oral corticosteroids treatment
|
Bronchial endoscopy will be performed after clinical examination and pulmonary function tests
5 biopsies will be done and analysed at the end of recruiting to assess monomeric GTP Rac1 protein expression and activity on bronchial biopsies
For participants who had signed ancillary research consent
|
Other: Mild to moderate Asthma
patients affected with untreated mild to moderate asthma
|
5 biopsies will be done and analysed at the end of recruiting to assess monomeric GTP Rac1 protein expression and activity on bronchial biopsies
For participants who had signed ancillary research consent
|
Other: Controlled Sample
smooth muscle cells from Tracheobronchial rings of non-asthmatic cadaveric donor
|
5 biopsies will be done and analysed at the end of recruiting to assess monomeric GTP Rac1 protein expression and activity on bronchial biopsies
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Activity level and expression of Rac1 protein in airway smooth muscle cells of asthmatics vs non asthmatics samples
Time Frame: at day 15
|
Mean of fluorescence intensity of Rac1-GTP and Rac1 in paraffinised biopsies of airway smooth muscle cells
|
at day 15
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessing any difference between activity level and expression of Rac1 in airway smooth muscle cells of severe versus non severe asthmatic patients.
Time Frame: at day 15
|
Mean of fluorescence intensity of Rac1-GTP and Rac1 in paraffinised biopsies of airway smooth muscle cells.
|
at day 15
|
Assessing any correlation between Rac1-GTP/Rac1 ratio signal, pulmonary function tests and clinical data
Time Frame: at day 15
|
Mean of fluorescence intensity of Rac1-GTP and Rac1 in paraffinised biopsies of airway smooth muscle cells.
|
at day 15
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RC16_0469
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
-
Johann Wolfgang Goethe University HospitalCompletedExercise-induced AsthmaGermany
Clinical Trials on Bronchial endoscopy
-
Azienda Socio Sanitaria Territoriale della Valle...RecruitingCopd | Bronchiectasis AdultItaly
-
Dr. Grace ParragaMcMaster UniversityCompleted
-
Assistance Publique - Hôpitaux de ParisUnknown
-
Guangzhou Institute of Respiratory DiseaseUnknown
-
National University Hospital, SingaporeUnknown
-
University Hospital, Clermont-FerrandRecruiting
-
Erasme University HospitalCompletedLung Cancer | Pulmonary DiseaseBelgium
-
Seoul National University HospitalCompletedDouble Lumen Tube IntubationKorea, Republic of
-
Regend TherapeuticsSouthwest Hospital, China; Tongji UniversityCompletedChronic Obstructive Pulmonary DiseaseChina